HCPLive Network

Pain Clinical Trial Reports

 
Brief summaries of recently launched clinical trials for post-operative pain, low back pain, pelvic pain, migraine, and other forms of chronic pain.
 
Efficacy of Gralise for Chronic Pelvic Pain
Sponsor: Rehabilitation Institute of Chicago
Study Drug: Gralise (gabapentin)
Estimated Enrollment: 36
Condition: Pelvic pain, prostatitis, interstitialcystitis, ulcerative colitis, irritable bowel syndrome
Study Site(s): Illinois
This phase IV study will “investigate the pain relieving effects of the study drug Gralise (a novel long-acting gabapentinoid) for people who experience chronic pelvic pain.” Patients will use an electronic pain diary for 15 weeks to record their “worst pain of the day” and the average of three other pain scores using a pain numeric rating scale. Participants will “start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose.”
 
Study of Oxycodone DETERx vs. Placebo in Opioid-Experienced and Opioid-naive Subjects with Moderateto-Severe Chronic Low Back Pain
Sponsor: Collegium Pharmaceutical, Inc.
Study Drug: Oxycodone DETERx
Estimated Enrollment: 350
Condition: Chronic low back pain
Study Site(s): Arizona, Florida, Indiana, Kansas, New York, Ohio, Oklahoma, South Carolina, Virginia, Washington
Investigators will “evaluate the analgesic efficacy of Oxycodone DETERx compared with placebo in opioid-experienced and opioid-naive subjects with moderate-to-severe chronic low back pain.” The primary outcome measures will be the change in average pain intensity measured by the change in PI-NRS scores from baseline to Week 12 of the maintenance phase of the study. Participants will receive placebo or 40-160 mg total of oxycodone DETERx per day, divided into two doses.
 
Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 Mcg for the Treatment of Post-operative Pain in Patients after Knee or Hip Replacement Surgery
Sponsor: AcelRx Pharmaceuticals, Inc.
Study Drug: Sufentanil NanoTab PCA System
Estimated Enrollment: 440
Condition: Postoperative pain
Study Site(s): Florida
Investigators will evaluate the efficacy and safety of the Sufentanil NanoTab PCA System/15 mcg for the management of acute postoperative pain after total unilateral knee or total unilateral hip replacement surgery. The primary outcome measure will be the “timeweighted summed pain intensity difference (SPID) over the 48-hour study period.” Patients who have undergone a replacement of the same knee or hip, or “who have taken an opioid for more than 30 consecutive days, at a daily dose of 15 mg or more of morphine (or equivalent), within the past 3 months prior to surgery,” are ineligible.
 
Influence of Body Size and Composition on Response to Hydromorphone in ED Patients with Acute Pain
Sponsor: Albert Einstein College of Medicine of Yeshiva University
Study Drug: Hydromorphone
Estimated Enrollment: 200
Condition: Acute pain
Study Site(s): New York
This study will “examine the association between two measures of body size/body composition and response to a standard dose of hydromorphone. The null hypothesis is that there is no association between the measures of body size/composition and response to 1 mg hydromorphone, and thus no difference between the associations. If a strong association exists between TBW or BMI and pain response, it will lend support for the importance of taking body size or composition into account when making decisions about hydromorphone dosing in the ED. It will lay the groundwork for future studies of analgesic dosing. This is of particular importance given the increasing prevalence of obesity in the US and other developed nations.”
 
Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception in Men with Chronic Pain Syndrome
Sponsor: Johns Hopkins University and Endo Pharmaceuticals
Study Drug: Fortesta (testosterone gel)
Estimated Enrollment: 70
Condition: Pain, low testosterone, hypogonadism
Study Site(s): Maryland
Researchers will study whether “testosterone replacement in men who take opioid-based pain medications and have low testosterone levels will show improvement in pain tolerance, pain perception and quality of life.” Primary outcomes measures are pain tolerance (measured using standard pressure pain, thermal pain perception, and cold pressor tests) and quality of life (measured using the Short Form-36 questionnaire).
 
Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine
Sponsor: Merck
Study Drug: MK-1602, rescue medication
Estimated Enrollment: 192
Condition: Migraine
Study Site(s): Arizona, California, Florida, Indiana, Massachusetts, Missouri, New York, Ohio, Texas, Utah, Virginia
This study will attempt to “characterize the pharmacokinetics of MK-1602 in the treatment of acute migraine, including the influence of demographic and other variables on MK-1602 pharmacokinetics, and to evaluate the relationship between MK-1602 concentrations and efficacy of the drug.” Primary outcome measures include “dry blood spot” MK-1602 concentration two hours post-dose on migraine treatment day and pain freedom and relief two hours post-dose on migraine treatment day. Researchers will also monitor subjects for absence of phonophobia, photophobia, and nausea two hours post-dose, sustained pain freedom and/or relief from 2-24 hours post-dose on migraine treatment day, and total migraine freedom at two hours and at 2-24 hours post-dose on treatment day.
 
 
Further Reading
Atherosclerotic internal carotid artery disease is a major contributor to ischemic stroke. Surgeons use a combination of carotid artery and brain imaging to determine if patients have symptomatic carotid stenosis. However, there remains widespread disagreement on the threshold, timing, and best technical approach to carotid revascularization in symptomatic patients.
The FDA has cleared a blood test that can screen patients, especially black women, for coronary heart disease.
The chemical compound indazole chloride (Ind-Cl) initiated long lasting relief in mice models of multiple sclerosis.
More Reading
$related2$